Vol. 21/No. 7 | OncologyLive

Immunotherapy Biomarker Testing Depends on Tumor Type

April 01, 2020

A Working Group of the European Society for Medical Oncology has determined that a decision tree on the sequential use of different tests in immunotherapy decision-making cannot be a general one for all cancers but should be designed on the basis of the specific tumor type.

Investigators Seek to Improve SOC in Cervical Cancer

April 01, 2020

Motivated to move the needle in cervical cancer, investigators are adding durvalumab to standard-of-care concurrent chemoradiation therapy and brachytherapy to determine whether PD-L1 blockade is a key to improving survival outcomes.

First CRISPR Cancer Results Fuel Hope

March 30, 2020

Results from the first FDA-approved in-human trial of CRISPR-edited T cells for cancer treatment suggest that such therapies can be used safely in patients, allaying some of the concerns about potential AEs and advancing progress toward the development of more effective cell-based immunotherapies.

Hematopoietic Stem Cell Transplant: A Viable Option for Older Patients With AML

March 28, 2020

The challenge in caring for older patients is developing a risk-adapted strategy that best meets the patients’ identified goals and accounts for a realistic assessment of hematopoietic stem cell transplantation suitability.

Public Health Sector Groans Under Burden of Multiple Epidemics

March 27, 2020

This has been a difficult time for public health policy and regulatory organizations struggling to deal with rapidly changing and unquestionably serious societal health-related issues and concerns. The list of problems these agencies must tackle is growing, and so are the questions about the strategies that should be used to address these threats.